Oral small molecule GLP-1 receptor agonist
Lotiglipron 140 mg tablet once daily
LOTI_PO_140MG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.24 (-9.55 to 1.94) | 0.70 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.75 (0.27 to 8.51) | 0.32 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.99 (3.55 to 18.51) | 0.10 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 8.80 (4.48 to 17.02) | 0.10 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 6.84 (2.64 to 18.09) | 0.22 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.20 (0.97 to 4.73) | 0.36 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 6.83 (2.93 to 15.96) | 0.07 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.96 (0.05 to 15.93) | 0.45 |
| Type 2 diabetes (adults) | Acute kidney injury | longest follow-up | Placebo | HR 0.56 (0.01 to 27.68) | 0.53 |
| Overweight or obesity without diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -4.20 (-9.97 to 3.15) | 0.34 |
| Overweight or obesity without diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.79 (0.23 to 10.06) | 0.39 |
| Overweight or obesity without diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 7.09 (2.72 to 18.55) | 0.16 |
| Overweight or obesity without diabetes (adults) | Nausea | longest follow-up | Placebo | HR 6.60 (3.24 to 13.19) | 0.22 |
| Overweight or obesity without diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 5.85 (1.89 to 18.85) | 0.38 |
| Overweight or obesity without diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 1.63 (0.64 to 4.00) | 0.57 |
| Overweight or obesity without diabetes (adults) | Constipation | longest follow-up | Placebo | HR 4.99 (1.74 to 14.19) | 0.17 |